xiidra
Showing 1 - 17 of 17
Dry Eye Trial in Waterloo (Xiidra)
Recruiting
- Dry Eye
- Xiidra
-
Waterloo, Ontario, CanadaCentre for Ocular Research & Education
Jan 26, 2023
Dry Eye Trial in Mississauga (Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution))
Completed
- Dry Eye
- Reproxalap Ophthalmic Solution (0.25%)
- Xiidra® (5% lifitegrast ophthalmic solution)
-
Mississauga, Ontario, CanadaCliantha Research
Sep 26, 2022
Ocular Discomfort in Glaucoma Patients Using Multiple Topical
Recruiting
- Glaucoma
- Ocular Surface Disease
- Xiidra (Lifitegrast ophthalmic solution) 5%
-
Fountain Valley, CaliforniaDoheny Eye Center UCLA
Oct 31, 2022
Corneal Disease Trial in Abu Dhabi (Xiidra 5% Ophthalmic Solution)
Recruiting
- Corneal Disease
- Xiidra 5% Ophthalmic Solution
-
Abu Dhabi, United Arab EmiratesINMC
Sep 7, 2021
Dry Eye Trial in Wilkes-Barre (Lifitegrast 5% Ophthalmic Solution)
Enrolling by invitation
- Dry Eye
- Lifitegrast 5% Ophthalmic Solution
-
Wilkes-Barre, PennsylvaniaBucci Laser Vision
Sep 28, 2021
Dry Eye Syndromes Trial in Kansas City (Lifitegrast Ophthalmic, Systane Free, Lipiflow)
Active, not recruiting
- Dry Eye Syndromes
- Lifitegrast Ophthalmic
- +2 more
-
Kansas City, Missourijoseph Tauber
Oct 25, 2022
Dry Eye Trial in New York (Lifitegrast 5% Ophthalmic Solution, Lifitegrast Ophthalmic Solution Vehicle)
Not yet recruiting
- Dry Eye
- Lifitegrast 5% Ophthalmic Solution
- Lifitegrast Ophthalmic Solution Vehicle
-
New York, New YorkState University of New York College of Optometry Clinical Visio
Aug 16, 2022
Dry Eye Trial in Nashville (nanomicellular cyclosporine 0.09%, Lifitegrast)
Recruiting
- Dry Eye
- nanomicellular cyclosporine 0.09%
- Lifitegrast
-
Nashville, TennesseeToyos Clinic
Oct 4, 2021
Dry Eye Syndromes Trial in Miami (Self retained cryopreserved amniotic membrane, lifitegrast ophthalmic solution)
Terminated
- Dry Eye Syndromes
- Self retained cryopreserved amniotic membrane
- lifitegrast ophthalmic solution
-
Miami, FloridaCenter of Excellence in Eye Care
Oct 5, 2020
Dry Eye Disease Trial in United States (SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium
Completed
- Dry Eye Disease
- SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)
- +6 more
-
Phoenix, Arizona
- +39 more
Apr 10, 2022
Dry Eye, Dry Eye Syndromes, Dry Eyes Chronic Trial in New York (Lifitegrast 5% Ophthalmic Solution)
Withdrawn
- Dry Eye
- +2 more
- Lifitegrast 5% Ophthalmic Solution
-
New York, New YorkWeill Cornell Ophthalmology
Feb 10, 2021
Contact Lens Dry Eye Trial in Birmingham (Lifitegrast)
Withdrawn
- Contact Lens Dry Eye
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Oct 23, 2018
Ocular Surface Disease, Dry Eye Syndromes Trial in Toronto (Autologous platelet rich plasma eye drops)
Unknown status
- Ocular Surface Disease
- Dry Eye Syndromes
- Autologous platelet rich plasma eye drops
-
Toronto, Ontario, CanadaToronto Western Hospital
Oct 22, 2020
Dry Eye Trial in Washington (Eyelash prostheses, 5.0% Lifitegrast Ophthalmic Solution)
Unknown status
- Dry Eye
- Eyelash prostheses
- 5.0% Lifitegrast Ophthalmic Solution
-
Washington, MissouriComprehensive Eye Care
Oct 1, 2018